ArticleAnnals of medicine and surgery (2012)2025
Safety and efficacy of darolutamide in combination with androgen-deprivation therapy for prostate cancer: a systematic review and meta-analysis.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer is the second most common cancer in men. Androgen deprivation therapy (ADT) is the standard treatment, but many patients develop resistance, leading to metastatic castration-resistant prostate cancer (CRPC). Darolutamide, an androgen receptor inhibitor, has shown promise in treating prostate cancer, but its combination with ADT remains under-researched. This study evaluated the safety and efficacy of darolutamide with ADT in patients with hormone-sensitive prostate cancer and CRPC compared to ADT plus placebo. Methods: We searched electronic databases for randomized controlled trials on darolutamide + ADT in prostate cancer. The primary outcome was overall survival, and secondary outcomes included pain progression, time to subsequent antineoplastic therapy, and adverse events (fatigue, bone fractures, falls, mental disorders, rash, hypertension, and serious events). Results: Four studies ( Conclusion: Darolutamide + ADT improves outcomes for PC patients but presents safety concerns, including bone fractures and hypertension. Further trials are needed for optimal patient selection and long-term management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.